EPTIS
BAM Logo

Biotherapy : Rituximab

[Biotherapie : Rituximab]

EPTIS factsheet 1051045 | Last revision 2023-05-24 | URL: https://www.eptis.bam.de/pts1051045 https://www.eptis.bam.de/pts1051045

PT provider
PT provider CTCB CTCB
Based in France
Language(s) English /French
Remarks All our biotherapy programs include a clinical case to interpret
Keywords
Product groups Health care / medical devices
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
human serum Quantification of rituximab serum concentrations all methods
Anti-Infliximab antibodies detection and quantification all methods
Aims of the PT scheme
Target group of participants merdical laboratories / no restriction to participation but possible extra charges according to the country
Linked to specific legislation / standards no
Additional, subsidiary aims
Number of participants 7
Accredited or otherwise reviewed by a 3rd party

Accredited by none on the basis of

no

Operation is commissioned / requested by no
Fees and frequency
Participation fee 462 euros
Regularly operated Yes (3 surveys per year (one sample per survey))
Year of first operation 2023
Contact details of the PT provider
Provider Contact person
CTCB
33 route de Bayonne
31300 TOULOUSE
France

Phone: +33 (0)5 34 51 49 80
Fax: +33 (0)1 57 67 25 90
Web: https://www.ctcb.com/ https://www.ctcb.com/
Dr Stéphanie Albarede
Phone: +33 (0)5 34 51 49 80
Fax: +33 (0)1 57 67 25 90
Email: s.albarede@ctcb.com s.albarede@ctcb.com
If you find any mistakes please contact the responsible EPTIS coordinator in France, Mr Patrick Bironneau. Mr Patrick Bironneau.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5